undamentalytics Newsletter
Sign in

Lucid Diagnostics Inc. key statistics and ratios

In fiscal 2025, Lucid Diagnostics Inc. had an operating margin of -1054.8%, debt equal to 219.5% of equity and a current ratio of 1.31. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Gross margin100.0%100.0%—−63.3%−41.7%—
Operating margin<−999%<−999%<−999%<−999%<−999%−930.9%
Net margin<−999%<−999%<−999%<−999%<−999%−959.8%
Free-cash-flow margin<−999%<−999%—<−999%−992.0%−860.8%
Return on equity−51.3%−144.4%————
Return on assets−47.6%−122.8%−176.2%−157.0%−163.0%−131.6%
Asset turnover0.010.010.080.150.130.14
Current ratio13.452.890.751.071.311.33
Debt to equity—0.0%—345.0%219.5%215.1%
Interest cover (operating income ÷ interest)n/mn/mn/mn/mn/mn/m
R&D as % of revenue>999%>999%298.7%137.9%120.7%99.0%
SG&A as % of revenue4.2%—————
Capital spending as % of revenue172.4%848.8%—6.8%4.2%0.0%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 3 checks passed · June 30, 2026
What it owns · $39m
Short-term assets $37mLonger-term assets $2m
What it owes, and who funded it · $39m
Short-term liabilities $28mLonger-term liabilities $1mShareholders' equity $11m
  • Short-term assets cover short-term liabilities $37m of assets due within a year against $28m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $37m short-term assets against $503,000 of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Operating income of −$51m against $18,000 of interest.

From Lucid Diagnostics Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

17 /100

Weak moat

How hard Lucid Diagnostics's competitive advantage looks for rivals to wear away, judged from 5 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -134.2% of total assets over 5 years.

  • Durability 10 / 20

    Operating margin has been a median -1172.8%; its worst year was -6967.6%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 5 years, at a median -1179.9% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: LUCD vs NRXSBIAF vs LUCDLUCD vs MCTA

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Lucid Diagnostics Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Lucid Diagnostics Inc.